Rappta Therapeutics Oy has signed an exclusive global license agreement with Springworks Therapeutics Inc. for RPT-04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Springworks will be responsible for global development and commercialization of RPT-04402, now named SW-3431, and expects to file an IND application by year-end.
An exclusive licensing agreement with Insilico Medicine Inc. grants Menarini’s Stemline Therapeutics Inc. the global rights to develop and commercialize a preclinical small molecule for high unmet needs in oncology.
Gilead Sciences Inc. and Leo Pharma A/S have established a strategic partnership to accelerate the development and commercialization of Leo’s small-molecule oral STAT6 programs for the treatment of inflammatory diseases.
Zai Lab Ltd. has entered into a new strategic collaboration and worldwide license agreement with Medilink Therapeutics (Suzhou) Co. Ltd. to use Medilink’s TMALIN antibody-drug conjugate (ADC) platform.
Climb Bio Inc. has entered into an exclusive license agreement with Beijing Mabworks Biotech Co. Ltd. for rights to develop and commercialize MIL-116 (now CLYM-116), an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy, in the territory outside of Greater China.
Alesta Therapeutics BV has closed an oversubscribed €65 million (US$67 million) series A financing round designed to support development of its two small-molecule therapeutics.
Celmatix Therapeutics (Celmatix Inc.) has announced a new drug program for endometriosis, with the development of a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The company’s aim to focus on JNK inhibitors with greater specificity for JNK1 and JNK3 than for JNK2 led it to license lead compounds from Baylor College of Medicine.
RSS
